The 2019 American Society of Hematology (ASH) Annual Meeting was held in Orlando, Florida from December 7-10, 2019. The meeting included findings from early clinical results to updated results from key trials. Selected conference highlights included new CAR-T therapy data from the BCMA-targeting, LCAR-B38M, for the treatment of relapsed/refractory multiple myeloma, anti-CD19 CAR-T, KTE-X19, for relapsed/refractory mantle cell lymphoma, and CD19 directed, lisocabtagene maraleucel, for the treatment of relapsed/refractory large B- cell lymphoma. Other follow-up results include the triple combination of TG-1303 (ublituximab, umbralisib) and Venclexta for relapsed/refractory chronic lymphocytic leukemia (CLL) and mosunetuzumab for relapsed or refractory B-cell NHL. Additional key pipeline updates for more established drugs were featured including Blincyto for relapsed acute lymphoblastic leukemia and Calquence for CLL.

This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.

For the full report, download the PDF version at the top of the page. A full list of ASH events is also available for download as an Excel file.

For our disclosures, please read the Biomedtracker Research Standards.